RADIATION THERAPY ONCOLOGY GROUP
RTOG 0837
RANDOMIZED, PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS CEDIRANIB VERSUS CONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS PLACEBO IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
RTOG 0837
RANDOMIZED, PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS CEDIRANIB VERSUS CONVENTIONAL CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS PLACEBO IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Protocol Participation Information
- Credentialing
- Credentialing Requirements
- Facility Questionnaire: Part I is required for this protocol.
- How to Participate
- Digital Data Submission Procedures
- Digital Data Submission Information (DDSI) Form
- Data Submission Check list
- ATC Compliant Treatment Planning Systems
- Structure Names
- Protocol Text (http://www.rtog.org/)
Back to protocols
